In disease resistant to irinotecan-based therapies, the oxaliplatin (FOLFOX4) regimen had superior efficacy to 5-FU/FA alone in a pivotal phase III trial (n = 816). Response rates and median durations of progression-free survival were 9.6% vs 0.7% and 5.6 vs 2.6 months, respectively. An ...
Administer oxaliplatin/fluorouracil/leucovorin (FOLFOX4) regimen over 2 consecutive days.On day 1, administer oxaliplatin 85 mg/m2 concurrently with leucovorin 200 mg/m2 (in separate containers) by IV infusion over 2 hours. Then administer fluorouracil 400 mg/m2 by IV injection over 2–4 minutes...
A total of 13 randomized clinical trials involving 940 Chinese patients with advanced (stage IV) colorectal cancer compared herbal medicines plus the FOLFOX-4 regimen with the FOLFOX-4 regimen alone. Although 58 different herbs and/or extracts were used in 7 studies, A. membranaceus was the ...
This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM ap...
FOLFOX alone has increased total average cost by 14%. New treatments have not substituted other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes...
Efficacy, safety, and immunogenicity of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: results of a randomized, double-blind phase III study. BioDrugs. 2021;35(4):445-458. doi:10.1007/s40259-021-00484-9Cross...
A more attainable goal in this area of pharmacological enquiry is the identification of proteomic profiles that will permit oncologists to accurately predict a lack of response to a given regimen, which would be useful for adapting treatment to the personal situation of each patient. Keywords: ...
For instance, based on promising results in a single-arm phase 2 study, SWOG 1815 is currently testing a triplet regimen of cisplatin, gemcitabine, and nab-paclitaxel (NCT03768414) [5] and KHBO1401-MITSUBA study in Japan is testing a triplet regimen of (gemcitabine, cisplatin, and S-1) ...
If KRAS mutation in codon 12 or 13 is detected, use of cetuximab is not recommended.Under investigation for use in combination with chemotherapy regimens (e.g., irinotecan/fluorouracil/leucovorin [FOLFIRI], oxaliplatin/fluorouracil/leucovorin [FOLFOX]) for the first-line† [off-label] treatment ...
Coincidentally, the incidence of CIT increased in oxaliplatin-based chemotherapy25,31,33. Our real world data also confirmed that oxaliplatin was positively correlated with CIT. This suggests that for intractable CIT induced by XELOX, We could try replacing it with FOLFOX. Of course, we could ...